Publications by authors named "Valenti L"

Background: Glioblastoma (GBM) is a lethal brain tumor characterized by the glioma stem cell (GSC) niche. The V-ATPase proton pump has been described as a crucial factor in sustaining GSC viability and tumorigenicity. Here we studied how patients-derived GSCs rely on V-ATPase activity to sustain mitochondrial bioenergetics and cell growth.

View Article and Find Full Text PDF

Surface biofunctionalization with structurally perturbed albumin, as well as with other plasmatic proteins, inhibits the initial bacterial adhesion and biofilm formation, involved in numerous healthcare-associated infections. In fact, we have reported this protective effect with thermally treated plasmatic proteins, such as albumin and fibrinogen, adsorbed on flat silica surfaces. Here, we show that albumin biofunctionalization also works properly on flat Ti6Al4V substrates, which are widely used to fabricate medical devices.

View Article and Find Full Text PDF

Background: The global burden of metabolic diseases is increasing, but estimates of their impact on primary liver cancer are uncertain. We aimed to assess the global burden of primary liver cancer attributable to metabolic risk factors, including high body mass index (BMI) and high fasting plasma glucose (FPG) levels, between 1990 and 2021.

Methods: The total number and age-standardized rates of deaths and disability-adjusted life years (DALYs) from primary liver cancer attributable to each metabolic risk factor were extracted from the Global Burden of Disease Study 1990-2021.

View Article and Find Full Text PDF

The topic of sustainable water management has become of paramount importance at a global level, especially when considering the high-amount of water used in agriculture, which is a threat to water resource balance. Focused on 38 inventories of nonirrigated vineyard management in the Franciacorta wine-growing region in Italy, this study aims to understand how agronomic practices impact water resources. The integrated statistical approach, based on generalized linear models, reveals how context variables influence different water footprint indicators, such as water scarcity, acidification and freshwater ecotoxicity.

View Article and Find Full Text PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by an excess of lipids, mainly triglycerides, in the liver and components of the metabolic syndrome, which can lead to cirrhosis and liver cancer. While there is solid epidemiological evidence that MASLD clusters with cardiometabolic disease, several leading genetic risk factors for MASLD do not increase the risk of cardiovascular disease, suggesting no causal relationship between MASLD and cardiometabolic derangement. In this work, we leveraged measurements of visceral adiposity identifying 27 previously unknown genetic loci associated with MASLD (n = 36,394), six replicated in four independent cohorts (n = 3,903).

View Article and Find Full Text PDF

Background: Metabolic risk factors are a significant cause of global burden among adolescents and young adults, but there is a lack of attention to the burden attributable to these metabolic risk factors globally.

Aims: This study aims to provide comprehensive estimates of five important metabolic risk factors and the attributable disease burden in people aged 15-39 years from 1990 to 2021, based on the Global Burden of Disease Study (GBD) database.

Methods: Global total deaths and disability-adjusted life years (DALYs) were used to describe the burden attributable to five common metabolic risk factors, including high fasting plasma glucose (FPG), high low-density lipoprotein cholesterol (LDL-C), high systolic blood pressure (SBP), high body mass index (BMI), and kidney dysfunction, in adolescents and young adults.

View Article and Find Full Text PDF
Article Synopsis
  • - Obesity is a major global health concern, with a significant rise in deaths and disability-adjusted life years (DALYs) linked to high body mass index (BMI) from 1990 to 2021, notably increasing by over 2.5 times for both genders.
  • - The main health issues associated with high BMI in 2021 included diabetes, heart disease, and stroke, with low-middle socio-demographic index (SDI) countries experiencing the largest increase in disease burden.
  • - The findings call for urgent monitoring and intervention efforts to address the growing health impact of high BMI from 1990 to 2021, especially given the stable death rates for women and rising rates for men.
View Article and Find Full Text PDF

Aims: To compare the efficacy of thyroid hormone receptor beta (THR-β) agonists, fibroblast growth factor 21 (FGF-21) analogues, glucagon-like peptide-1 receptor agonists (GLP-1RAs), GLP-1-based polyagonists, and pan-peroxisome proliferator-activated receptor (Pan-PPAR) agonists in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods: A database search for relevant randomized double-blind controlled trials published until July 11, 2024, was conducted. Primary outcomes were the relative change in hepatic fat fraction (HFF) and liver stiffness assessed non-invasively by magnetic resonance imaging proton density fat fraction and elastography.

View Article and Find Full Text PDF

Background & Aims: The loss of ovarian functions defining menopause leads to profound metabolic changes and heightens the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). Although estrogens primarily act on the female liver through estrogen receptor alpha (ERα), the specific contribution of impaired ERα signaling in triggering MASLD after menopause remains unclear.

Methods: To address this gap in knowledge, we compared the liver transcriptomes of sham-operated (SHAM) and ovariectomized (OVX) control and liver ERα knockout (LERKO) female mice by performing RNA-Seq analysis.

View Article and Find Full Text PDF
Article Synopsis
  • Metabolic dysfunction-associated fatty liver disease (MAFLD) is a rising cause of chronic liver disease globally, prompting the need for dietary intervention strategies.
  • A panel of 55 international experts conducted a study to reach a consensus on dietary modifications for preventing MAFLD, covering various aspects from epidemiology to management.
  • Recommended strategies include following a balanced diet, increasing whole grains and plant-based foods, and reducing red meat and processed foods, along with advocating for physical activity and possibly maintaining Mediterranean or DASH diets.
View Article and Find Full Text PDF

Background & Aims: Porto-sinusoidal vascular disorder (PSVD) is a group of vascular disorders characterized by lesions involving portal venules and sinusoids, irrespective of the presence of portal hypertension. Liver biopsy is essential for diagnosis. In a single-center study, we demonstrated high rates of PSVD in patients with persistently elevated gamma-glutamyltransferase (GGT).

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the relationship between plasma hepcidin levels and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) over an average follow-up of 55.6 months.
  • Out of 213 T2DM patients, those with higher hepcidin levels (3rd tertile) had a significantly doubled risk of experiencing adverse cardiovascular outcomes compared to those with lower levels (1st and 2nd tertiles).
  • The association remained strong even after adjusting for various cardiovascular risk factors and other potential confounders, indicating that higher hepcidin could predict increased mortality and cardiovascular events in T2DM patients.
View Article and Find Full Text PDF

Background: Common metabolic diseases, such as type 2 diabetes mellitus (T2DM), hypertension, obesity, hypercholesterolemia, and metabolic dysfunction-associated steatotic liver disease (MASLD), have become a global health burden in the last three decades. The Global Burden of Disease, Injuries, and Risk Factors Study (GBD) data enables the first insights into the trends and burdens of these metabolic diseases from 1990 to 2021, highlighting regional, temporal and differences by sex.

Methods: Global estimates of disability-adjusted life years (DALYs) and deaths from GBD 2021 were analyzed for common metabolic diseases (T2DM, hypertension, obesity, hypercholesterolemia, and MASLD).

View Article and Find Full Text PDF
Article Synopsis
  • The review highlights the recent approval of resmetirom for treating metabolic dysfunction-associated steatohepatitis (MASH), a liver disease related to obesity, emphasizing its potential impact on global health and the need for a multidisciplinary management approach.* -
  • Resmetirom is effective in treating MASH and has received FDA approval, but its safety, potential adverse events, and effectiveness across different populations require further study to optimize patient outcomes.* -
  • A comprehensive treatment strategy is recommended, combining resmetirom with lifestyle changes and metabolic and bariatric surgery (MBS), to enhance liver and overall health for individuals suffering from MASH.*
View Article and Find Full Text PDF

Recent advances in the genetics of metabolic dysfunction-associated steatotic liver disease (MASLD) are gradually revealing the mechanisms underlying the heterogeneity of the disease and have shown promising results in patient stratification. Genetic characterization of the disease has been rapidly developed using genome-wide association studies, exome-wide association studies, phenome-wide association studies, and whole exome sequencing. These advances have been powered by the increase in computational power, the development of new analytical algorithms, including some based on artificial intelligence, and the recruitment of large and well-phenotyped cohorts.

View Article and Find Full Text PDF

Background: Metabolic syndrome (MetS) is a cluster of medical conditions and risk factors correlating with insulin resistance that increase the risk of developing cardiometabolic health problems. The specific criteria for diagnosing MetS vary among different medical organizations but are typically based on the evaluation of abdominal obesity, high blood pressure, hyperglycemia, and dyslipidemia. A unique, quantitative and independent estimation of the risk of MetS based only on quantitative biomarkers is highly desirable for the comparison between patients and to study the individual progression of the disease in a quantitative manner.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic liver diseases, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), are widespread but poorly understood by many, highlighting the need for better awareness and knowledge transfer.
  • An analysis of Google search trends from 2004 to 2021 indicated that interest in MASLD has increased, while interest in its severe form (MASH) and viral hepatitis C has decreased; queries for viral hepatitis B remained stable but focused mainly on vaccination.
  • The search habits show that most users favor simpler, native language terms over complex medical jargon, indicating that public interest is led by non-experts and not significantly influenced by new medical advancements.
View Article and Find Full Text PDF

Despite extensive global research into genetic predisposition for severe COVID-19, knowledge on the role of rare host genetic variants and their relation to other risk factors remains limited. Here, 52 genes with prior etiological evidence were sequenced in 1,772 severe COVID-19 cases and 5,347 population-based controls from Spain/Italy. Rare deleterious TLR7 variants were present in 2.

View Article and Find Full Text PDF

Background: Artificial intelligence (AI)-based chatbots have shown promise in providing counseling to patients with metabolic dysfunction-associated steatotic liver disease (MASLD). While ChatGPT3.5 has demonstrated the ability to comprehensively answer MASLD-related questions in English, its accuracy remains suboptimal.

View Article and Find Full Text PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition. MASLD is a sexually dimorphic condition, with its development and progression influenced by sex chromosomes and hormones. Estrogens typically protect against, whereas androgens promote, MASLD.

View Article and Find Full Text PDF

Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.

Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.

View Article and Find Full Text PDF

To identify the mechanism underlying macrosteatosis (MaS)-related graft failure (GF) in liver transplantation (LT) by multi-omics network analysis. The transcriptome and metabolome were assayed in graft and recipient plasma in discovery ( = 68) and validation ( = 89) cohorts. Differentially expressed molecules were identified by MaS and GF status.

View Article and Find Full Text PDF